A perspective on the current management of advanced colorectal cancer

摘要: Although the median survival of patients with advanced disease has progressively increased, colorectal cancer remains a major worldwide health problem, approximately 1 million new cases and 500,000 deaths every year. At 2013 World Congress on Gastrointestinal Cancers, investigators have recently dealt many clinically relevant questions, such as preferred biologic drug to be used upfront in KRAS wild-type tumors, optimal treatment intensity, most suitable maintenance strategy, need for deeper molecular information when using EGFR inhibitors use antiangiogenic drugs elderly. Briefly summarizing all news coming from this moving landscape, article focuses results randomized Phase III trials presented at meeting.